Physicochemical Properties
| Molecular Formula | C17H15F3N2O4 |
| Molecular Weight | 368.307214975357 |
| Exact Mass | 368.098 |
| CAS # | 2745108-35-2 |
| PubChem CID | 162371278 |
| Appearance | Typically exists as solid at room temperature |
| LogP | 3.2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 4 |
| Heavy Atom Count | 26 |
| Complexity | 515 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | GHJDMUOTXYVBEB-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C17H15F3N2O4/c1-9(23)12-7-13(15(26-2)8-14(12)24)22-16(25)21-11-5-3-4-10(6-11)17(18,19)20/h3-8,24H,1-2H3,(H2,21,22,25) |
| Chemical Name | 1-(5-acetyl-4-hydroxy-2-methoxyphenyl)-3-[3-(trifluoromethyl)phenyl]urea |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | TOPK-p38/JNK-IN-1 (Compound B12) (10 µM, 1 hour) suppresses NO generation in RAW264.7 cells [1]. Compound B12: TOPK-p38/JNK-IN-1 (0-100 µM, 24 hours for RAW264).7 cells; 0-50 µM, 6 hours for HaCaT cells) demonstrates dose-dependent inhibition of cell growth [1]. Compound B12: TOPK-p38/JNK-IN-1 (0-10 µM), 1 hour in RAW264.7 cells; 6 hours in HaCaT cells) prevents TOPK/NF-jB/p38/JNK from being activated by LPS [1]. |
| ln Vivo | Psoriasis can be improved by TOPK-p38/JNK-IN-1 (Compound B12); inbred 6–8 week old female BALB/c mice; 20–40 mg/kg; IG, once daily, 7 days per group [1]. The illness is similar to skin inflammation. |
| Cell Assay |
Cell Viability Assay[1] Cell Types: RAW264.7 Cell Line Tested Concentrations: 4 µM, 20 µM and 100µM Incubation Duration: 24 h Experimental Results: Inhibition of cell proliferation in a dose-dependent manner. Cell proliferation assay [1] Cell Types: HaCaT cell line. Tested Concentrations: 0.78 µM, 1.56 µM, 3.125 µM, 6.25 µM, 12.5 µM, 25 µM and 50 µM. Incubation Duration: pretreatment with compound B12 for 6 hrs (hours) and incubation with LPS (100 μg/mL) for 24 hrs (hours). Experimental Results: Inhibited LPS-induced excessive proliferation of HaCaT cells in a dose-dependent manner. Western Blot Analysis[1] Cell Types: RAW264.7 and HaCaT cell lines. Tested Concentrations: 2.5 µM, 5 µM and 10 µM. Incubation Duration: pretreatment for 1 hour before SUV irradiation, co-treatment with LPS (0.5 μg/mL) for 0.5 hrs (hours) or 24 hrs (hours), and pretreatment for 6 hrs (hours). Experimental Results: It inhibited the expression of iNOS and COX-2 in a dose-dependent manner, affected the phosphorylation of TOPK, inhibited the phosphorylation of P38/JNK protein and the translocation of NF-κB p65 into |
| Animal Protocol |
Animal/Disease Models: Inbred 6-8 week old female balb/c (Bagg ALBino) mouse [1]. Doses: 20mg/kg, 40mg/kg Route of Administration: IG, one time/day, 7 days in each group. Skin inflammation was induced by applying 62.5 mg of IMQ cream topically to a 2 cm × 3 cm area of shaved back skin. Experimental Results: Successfully diminished scale, thickness, and erythema in psoriasis-like mice, and histopathologically attenuated hyperkeratosis, acanthocyte proliferation, and inflammatory cell infiltration. Inhibits the expression of related proteins (p-STAT3, p-TOPK, TOPK, p-p38, p-JNKs, PCNA, p-H2AX) in mouse skin tissue in a dose-dependent manner. |
| References |
[1]. Discovery of novel paeonol-based derivatives against skin inflammation in vitro and in vivo. Journal of Enzyme Inhibition and Medicinal Chemistry, 37:1, 817-831. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7151 mL | 13.5755 mL | 27.1510 mL | |
| 5 mM | 0.5430 mL | 2.7151 mL | 5.4302 mL | |
| 10 mM | 0.2715 mL | 1.3576 mL | 2.7151 mL |